Oncoinvent ASA - Key information relating to subsequent offering
2026-09-23 00:16:43
Reference is made to the stock exchange announcement made by Oncoinvent ASA (the
"Company") on 22 September 2026 regarding the allocation of 1,531,000 new shares
in the Company in a private placement (the "Private Placement") and 119,000 new
shares in a retail offering, and a potential subsequent repair offering of up to
200,000 new shares at the same subscription price as in the Private Placement
and the retail offering (the "Subsequent Offering"). The Subsequent Offering
will, subject to applicable securities law, be directed towards existing
shareholders in the Company as of 22 September 2026, as registered in the
Company's register of shareholders with Euronext Securities Oslo on 24 September
2026, who (i) were not allocated shares in the Private Placement, and (ii) are
not resident in a jurisdiction where such offering would be unlawful or, would
(in jurisdictions other than Norway) require a prospectus, filing registration
or similar action.
The following key information is provided with respect to the Subsequent
Offering:
Date on which the terms and conditions of the Subsequent Offering were
announced: 22 September 2026
Last day including right: 22 September 2026
Ex-date: 23 September 2026
Record date: 24 September 2026
Date of approval: 22 September 2026 (subject to final approval by the board of
launch of the Subsequent Offering)
Maximum number of new shares: 200,000
Subscription price: NOK 90 per share
Shall the rights be listed: No
Other information: The Subsequent Offering is subject to, inter alia, completion
of the Private Placement, approval by the board of directors, registration of
the board authorization to increase the share capital granted by the annual
general meeting held on 20 May 2026 (under agenda item 13.4), and the
publication of a prospectus. Whether or not the Subsequent Offering will
ultimately take place, will depend inter alia on the development of the price of
the shares in the Company after completion of the Private Placement, and the
Company reserves the right in its sole discretion to not conduct or to cancel
the Subsequent Offering.
This information is published in accordance with the requirements of the
Continuing Obligations for Euronext Oslo Børs.
For further information, please contact:
Oystein Soug, Chief Executive Officer
Email: IR@oncoinvent.com
ntact:\
\
Oystein Soug\, Chief Executive Officer\
Email: IR@oncoinvent.com\